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Abstract
Background: Standard chemotherapy for poor-prognosis metastatic nonseminoma has
remained bleomycin, etoposide, and cisplatin (BEP) for many years; more effective
regimens are required.
Objective: To explore whether response rates with a new intensive chemotherapy
regimen, CBOP/BEP (carboplatin, bleomycin, vincristine, cisplatin/BEP), versus those
in concurrent patients treated with standard BEP justify a phase 3 trial.
Design, setting, and participants: We conducted a phase 2 open-label randomised trial
in patients with germ cell tumours of any extracranial primary site and one or more
International Germ Cell Cancer Collaborative Group poor-prognosis features. Patients
were randomised between 2005 and 2009 at 16 UK centres.
Intervention: BEP (bleomycin 30 000 IU)was composed of four cycles over 12wk. CBOP/
BEP was composed of 2  CBOP, 2  BO, and 3  BEP (bleomycin 15 000 IU).
Outcome measurements and statistical analysis: Primary end point was favourable
response rate (FRR) comprising complete response or partial response and normal
markers. Success required the lower two-sided 90% conﬁdence limit to exclude FRRs
<60%; 44 patients on CBOP/BEP gives 90% power to achieve this if the true FRR is 80%.
Equal numbers were randomised to BEP to benchmark contemporary response rates.
Results and limitations: A total of 89 patients were randomised (43 CBOP/BEP, 46 BEP);
40 and 41, respectively, completed treatment. CBOP/BEP toxicity, largely haematologic,
was high (96% vs 63% on BEP had Common Terminology Criteria for Adverse Events v.3
grade3). FRRswere 74% (90% conﬁdence interval [CI], 61–85)with CBOP/BEP, 61%with
BEP (90% CI, 48–73). After a median of 58-mo follow-up, 1-yr progression-free survival
(PFS) was 65% and 43%, respectively (hazard ratio: 0.59; 95% CI, 0.33–1.06); 2-yr overall
survival (OS) was 67% and 61%. Overall, 3 of 14 CBOP/BEP and 2 of 18 BEP deaths were
attributed to toxicity, one after an overdose of bleomycin during CBOP/BEP. The trial was
not powered to compare PFS.
Conclusions: The primary outcome was met, the CI for CBOP/BEP excluding FRRs <61%,
but CBOP/BEPwasmore
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Patient summary: In this study we tested a new, more intensive way to deliver a
combination of drugs often used to treat men with testicular cancer. We found that
response rates were higher but that the CBOP/BEP regimen caused more short-term
toxicity. Because most patients are diagnosed when their cancer is less advanced, it took
twice as long to complete the trial as expected. Although we plan to carry out a larger
trial, we will need international collaboration.
Trial registration: ISRCTN53643604; http://www.controlled-trials.com/ISRCTN53643604.
# 2015 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is anopenaccessarticleunder theCCBY license (http://creativecommons.
org/licenses/by/4.0/).
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The management of metastatic germ cell tumours (GCTs)
with platinum-based chemotherapy represents a major
success story. However, a poor prognostic group can be
defined that achieved cure rates <50% in an international
pooled analysis [1].
Attempts to improve outcomes include use of multiagent
regimens (eg, cisplatin, vincristine,methotrexate, bleomycin,
actinomycin D, cyclophosphamide, etoposide [POMB/ACE]
[2]; bleomycin, vincristine, cisplatin/etoposide, ifosfamide,
cisplatin, and bleomycin [BOP/VIP-B] [3]); newdrugs such as
ifosfamide [4], and high-dose chemotherapy [5–7], but none
proved superior to bleomycin, etoposide, and cisplatin (BEP)
in randomised trials. Rapid proliferation [8–12] in GCTs [13]
could contribute to treatment failure; therefore, the Royal
Marsden Testicular Tumour Unit developed an intensive
induction regimen (BOP/BEP) based onWettlaufer et al. [14].
Features included weekly cisplatin for 4 wk with weekly
bleomycin and vincristine for 6 wk. In weeks 2 and 4,
bleomycin was administered as 5-d infusions [15] rather
thanbolus injections [16]. Three coursesofBEP followedwith
bleomycin at 15 000 IU/wk. Later, carboplatin was added
(weeks 2 and 4), and cisplatin was given over 2 rather than
5 d (weeks 1 and 3). The resulting carboplatin, bleomycin,
vincristine, cisplatin/bleomycin, etoposide, cisplatin (CBOP/
BEP) regimen differed from BOP/VIP [3] in early dose
intensity, use of infusional bleomycin, and use of BEP in
the second treatment phasewith higher dose etoposide than
VIP [17].
CBOP/BEP results fromprevious studies [18,19] suggested
high activitywith increased toxicity. However, case selection
or improved management over time hinders historical
comparisons. This randomised phase 2 trial (ISRCTN
53643604) evaluated CBOP/BEP and BEP at the same time.2. Patients and methods
2.1. Patients
Applicable regulatory and ethics approvals and written informed
consent were obtained. Eligible patients were 16 yr of age with a
GCT of any extracranial primary site and International Germ Cell Cancer
Collaborative Group (IGCCCG) poor-prognosis features (mediastinal
primary, nonpulmonary visceral metastases, a-fetoprotein [AFP] >10
000 ng/ml, human chorionic gonadotropin [hCG]>50 000 IU/l, or lactase
dehydrogenase >10 times the upper limits of normal). Diagnoses were
based on histology or by elevated AFP and/or hCG in a patient with atesticular tumour, or unequivocally raised markers (AFP>1000 ng/ml or
hCG >5000 IU/l) in men <45 yr of age without a testis tumour but with
an otherwise appropriate clinical picture.
2.2. Study design
This open phase 2 multicentre trial randomised patients (1:1) to BEP or
CBOP/BEP. Eligible patients not deemed ﬁt enough to receive protocol
chemotherapycouldbe stabilisedwith low-dose chemotherapy (normally
cisplatin 20 mg/m2 or carboplatin area under the curve 3 and etoposide or
vincristine for 2 d) prior to enrolment. Central randomisation through the
trials unit used minimisation (with a random element) based on pre-
protocol chemotherapy, primary tumour site, and centre.
2.3. Treatment
The control arm comprised four 3-weekly cycles of Indiana-style BEP, and
the CBOP/BEP arm comprised six cycles over 15 wk (see Fig. 1 for doses).
Prophylactic granulocyte colony-stimulating factor (G-CSF) was
mandated (in week 5 of CBOP/BEP and during each BEP cycle in both
arms) from January 2008 following Independent Data Monitoring
Committee advice.
Assessments prior to each cycle included physical examination/
performance status; full blood count including AFP, hCG; chest x-ray;
and renal function (including magnesium) with creatinine clearance
performed during the ﬁrst two cycles of CBOP.
Dose adjustments were made for myelosuppression according to
day 1 counts and previous haematological toxicity; treatment cycles
were omitted during CBOP until recovery. Neutropenic sepsis was
treated immediately with broad-spectrum antibiotics. Dose modiﬁca-
tions were also recommended for renal impairment, allergic reactions,
and pulmonary or neurologic toxicity including permanent discontinu-
ation of bleomycin in the case of lung toxicity.
Following treatment, patients were reviewed with clinical examina-
tion, chest X-ray, and tumourmarkers every 2mo in year 1, every 3mo in
year 2, then every 6 mo until the end of year 5. Cross-sectional imaging
was performed: 2–4 wk from the end of treatment; to follow residual
disease every 6 mo until resolution (<1 cm), resected, or stable for 1 yr;
2 mo following surgical resection of tumour masses; and at the
investigator’s discretion. Surgical resection was advised for all non-
resolving masses >1 cm. Management of disease progression was at the
clinician’s discretion.
2.4. Outcome measures
Response was evaluated as previously described, and a response
category deﬁned as listed below; the primary end point was the
favourable response rate (FRR), the numerator comprising categories 1
and 2. Complete response was deﬁned as normal AFP/hCG and either no
clinical or radiologic evidence of disease, or complete resection of all
[(Fig._1)TD$FIG]
Fig. 1 – Chemotherapy regimens.
AUC = area under the curve; BEP = bleomycin, etoposide, and cisplatin; CBOP/BEP = carboplatin, bleomycin, vincristine, cisplatin/bleomycin, etoposide,
and cisplatin.
# Etoposide to be given at 100 mg/m2 daily over 5 d.
§ Cisplatin to be given at 20 mg/m2 daily for 5 d.
£ Cisplatin to be given at 50 mg/m2 days 1 and 2 or 20 mg/m2 daily for 5 d (weeks 1 and 3).
¢ Bleomycin to be given at 15 000 IU by 24-h infusion daily over 5 d.
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negative was deﬁned as normal AFP/hCG and no surgery or partial
resection only; no viable tumour was detected. Treatment failure was
deﬁned as the progressive rise of tumour markers at the end of
treatment, an increase in tumour masses or appearance of new lesions
not due to mature teratoma syndrome, or the presence of viable tumour
in resected specimens. A subset of the latter group, referred to as
no evidence of disease (NED) after surgery, was identiﬁed to include
patients with normal markers and completely resected nontestis masses
in which viable tumour was found.
Subsequently, recognising the testis as a sanctuary site, the Trial
Management Group (blinded to study data) agreed that patients
undergoing postchemotherapy orchidectomy with viable tumour found
would be included in the favourable response category if all other features
ﬁtted this category. The preﬁx late orchidectomy identiﬁes these patients
in the results.
Secondary end points were progression-free survival (PFS), overall
survival (OS), and toxicity. PFS was measured from randomisation to
date of progression or death from any cause; patients with treatment
failure, other than those in the NED subgroup, were counted as having anevent on day 1 to avoid bias due to longer treatment durationwith CBOP/
BEP. Progressive disease was deﬁned as rising tumourmarkers for>4wk
and/or increase in the size of lesions, or the appearance of new lesions
(excluding growing mature teratoma).
2.5. Statistical considerations
A single-stage Fleming design was used, assuming an FRR for CBOP/BEP
80% would warrant further study and a rate <60% that historical data
suggest with BEP [3] would not. With 44 patients randomised to CBOP/
BEP, the trial had 90%power to exclude response rates60%witha = 5%
(one-sided) when the true response rate was 80%. Thus ‘‘success’’ for
the primary analysis required the one-sided 95% conﬁdence limit
(equivalently, the lower limit of the 90% two-sided CI) to exclude rates
<60%. An equal numberwere randomised to BEP to benchmark the FRR;
the trial was not powered to compare arms deﬁnitively with respect to
efﬁcacy. Continuation to a phase 3 trial powered for PFS required
success as deﬁned earlier in the primary analysis, that the BEP FRR was
within the anticipated range, and that trial recruitment rate was
adequate.
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group was included as favourable responders; (2) the late orchidectomy
partial responsegroupwasexcluded fromthe favourableresponsecategory.
FRRs were also assessed according to receipt of pre-protocol stabilising
chemotherapy (planned subgroup analysis) and according to histologic
diagnosis (exploratory analysis). A per protocol population was deﬁned a
priori to include eligible patients receiving one cycle or more of protocol
chemotherapy; however, all patients met these criteria. Preplanned time-
to-event analyses included Kaplan-Meier curves for PFS and OS with
treatment hazard ratios (HRs) derived from Cox regression models.
3. Results
A total of 89 patients were randomised from 16 UK centres,
46 to BEP and 43 to CBOP/BEP (Fig. 2). Baseline character-
istics were well balanced (Table 1). Mean age was 30 yr
(range: 16–68); 18 (20%) hadmediastinal primary tumours.
Overall, 53 patients (60%) had diagnosis confirmed histo-
logically and 36 (40%) based on markers/clinical picture.
Twenty-four patients (27%) had pre-protocol low-dose
chemotherapy for stabilisation.
3.1. Treatment
Treatment completion rates for BEP and CBOP/BEP,
respectively, were 41 of 46 (89%) and 40 of 43 (93%);
reasons for early stopping were disease progression (2 BEP,
0 CBOP/BEP), toxicity-related death (1 BEP, 1 CBOP/BEP),
other early death (2 BEP, 1 CBOP/BEP), and toxicity (0 BEP,
1 CBOP/BEP). Dose modifications or omissions occurred in
34 CBOP/BEP patients (79%) versus 16 (35%) on BEP. For BEP,
these were most commonly omissions of bleomycin in
later cycles. For CBOP/BEP, omissions were most common[(Fig._2)TD$FIG]
Fig. 2 – Trial profile.
BEP = bleomycin, etoposide, and cisplatin; CBOP/BEP = carboplatin, bleomycin,
tumour; IGCCCG = International Germ Cell Cancer Collaborative Group.in cycle 3 (weeks 5 and 6): 15 patients (36%) who received
three or more cycles had one or more drug doses omitted
from cycle 3 including fourwhomissed this cycle altogether
(as mandated for significant myelosuppression) but went
on to complete treatment. In addition, three CBOP/BEP
patients were given bleomycin at 30 000 IU rather than
15 000 IU during the BEP cycles in error (in one case, all nine
weekly doses; in two cases, seven doses with the remaining
two omitted).
3.2. Toxicity and deaths during treatment
With CBOP/BEP, 95% had Common Terminology Criteria for
Adverse Events v.3 grade 3 symptoms during treatment
versus 63% of BEP patients (Table 2), largely due to
haematologic toxicity, particularly neutropenia that affect-
ed 25 (54%) and 36 (84%) patients, respectively; 7 (15%) and
13 (30%), respectively, had neutropenic fever. Grade 3–4
thrombocytopenia occurred in 8 (18%) BEP and 23 (54%)
CBOP/BEP patients.
Distinguishing between symptoms of severe disease,
toxicity, and intercurrent illness or infection made it
difficult to classify cause of death in several cases. Two
on-treatment deaths in the CBOP/BEP arm (one in a patient
who had received a bleomycin overdose) and one BEP death
3 mo after treatment were thought likely to be a result of
lung damage associatedwith bleomycin. Bleomycin toxicity
was also a possible contributory factor in three further
deaths (one BEP, two CBOP/BEP) from infective respiratory
conditions (postoperative adult respiratory distress syn-
drome [ARDS] [one], pneumonia [two]) that occurred 2–3
mo after completion of protocol chemotherapy.vincristine, cisplatin/bleomycin, etoposide, and cisplatin; GCT = germ cell
Table 1 – Baseline characteristics
BEP CBOP/BEP Overall
No. of patients 46 43 89
Age, yr
Mean (SD) 31.3 (10.7) 28.5 (8.8) 29.9 (9.9)
Site of primary tumour, n (%)
Testis 34 (72) 32 (74) 66 (74)
Mediastinum 9 (20) 9 (21) 18 (20)
Retroperitoneum 2 (4) 2 (5) 4 (4)
Other* 1 (4) 0 (0) 1 (1)
IGCCCG risk factors, n (%)
Raised markersy only 14 (30) 10 (23) 24 (27)
Mediastinal primary tumour only 7 (15) 4 (9) 11 (12)
NPVM only 9 (20) 10 (23) 19 (21)
Raised markers and mediastinal
primary
2 (4) 3 (7) 5 (6)
Raised markers and NPVM 14 (30) 14 (33) 28 (31)
Mediastinal primary and NPVM 0 (0) 2 (5) 2 (2)
Stabilising chemotherapy prior to
protocol treatment, n (%)
13 (28) 11 (26) 24 (27)
BEP = bleomycin, etoposide, and cisplatin; CBOP = carboplatin, bleomycin,
vincristine, cisplatin; IGCCCG = International Germ Cell Cancer Collaborative
Group; NPVM = nonpulmonary visceral metastases; SD = standard
deviation.
* Difﬁcult to determine between testis and retroperitoneum.
y a-Fetoprotein > 10 000 ng/ml, human chorionic gonadotropin> 50 000 IU/l,
or lactate hydrogenase> 10 times upper limit of normal.
Table 2 – Grade 3 or 4 worst toxicity during chemotherapy
Toxicity CTCAE
grade*
BEP,
n (%)
CBOP/BEP,
n (%)
Thrombocytopenia 3 4 (9) 6 (14)
4 4 (9) 17 (40)
Neutropenia 3 14 (30) 8 (19)
4 11 (24) 28 (65)
Fever with grade 3
or 4 neutropenia
3 0 (0) 7 (16)
4 0 (0) 0 (0)
Other haematologic
symptoms
3 9 (20) 20 (47)
(not speciﬁed) 4 0 (0) 7 (16)
Anorexia 3 3 (7) 3 (7)
4 0 (0) 0 (0)
Constipation 3 0 (0) 1 (2)
4 0 (0) 0 (0)
Diarrhoea 3 2 (4) 4 (9)
4 0 (0) 1 (2)
Nausea 3 2 (4) 8 (19)
4 0 (0) 1 (2)
Vomiting 3 2 (4) 4 (9)
4 0 (0) 1 (2)
Fever 3 0 (0) 8 (19)
4 0 (0) 1 (2)
Sensory neuropathy 3 0 (0) 1 (2)
4 0 (0) 0 (0)
Dermatologic 3 1 (2) 0 (0)
4 0 (0) 0 (0)
Fatigue 3 2 (4) 9 (21)
4 0 (0) 0 (0)
Auditory 3 0 (0) 1 (2)
4 0 (0) 0 (0)
Vascular 3 0 (0) 3 (7)
4 0 (0) 0 (0)
Cardiovascular 3 1 (2) 1 (2)
4 1 (2) 1 (2)
Pulmonary 3 2 (4) 3 (7)
4 1 (2) 1 (2)
Renal 3 0 (0) 0 (0)
4 0 (0) 0 (0)
Pain 3 3 (7) 6 (14)
4 0 (0) 0 (0)
Other toxicity 3 3 (7) 14 (33)
4 0 (0) 3y (7)
BEP = bleomycin, etoposide, and cisplatin; CBOP = carboplatin, bleomycin,
vincristine, cisplatin; CTCAE = Common Terminology Criteria for Adverse
Events v.3.
* As reported at the time of scheduled assessment. Any subsequent deaths
thought to be related to treatment are reported in the text.
y Pulmonary embolism; leukocytes; line infection.
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during treatment. In the BEP arm these were due to
haemorrhage of brain metastases when heparinised
(a complication of neutropenic sepsis management) and a
combination of severe disease, toxicity, and pneumonia
after the first week of BEP. In the CBOP/BEP arm they were
due to ARDS and septicaemia (a complication of neutrope-
nic sepsis that developed in the first week of treatment) and
tomultiorgan failure associatedwith sepsis in a patientwho
was not neutropenic.
The policy change mandating G-CSF prophylaxis led to
98% (previously 40%) of BEP patients and 76% (previously
47%) of CBOP/BEP patients receiving G-CSF in the required
cycles. However it did not have a substantial impact on the
incidence or grade of neutropenia or febrile neutropenia
(29% in CBOP/BEP before and after the protocol amend-
ment), although an impact on duration of symptoms (not
assessable) cannot be excluded.
3.3. Efficacy
Response was evaluated in all 89 patients (Table 3).
FRRs were 60.9% (90% CI, 47.7–73.0) for the BEP arm and
74.4% (90% CI, 61.2–84.9) for the CBOP/BEP arm. Results
from the sensitivity analyses (Table 3) were broadly
consistent.
The FRR was 58.3% (39.7–75.4%) in patients having pre-
protocol stabilising chemotherapy and 70.8% (60.1–79.9%)
in those that did not, and it was 64.2% (52.0–75.1%) in those
with a histologic diagnosis compared with 72.2% (57.4–
75.1%) in those without. The difference between arms
appearedmoremarked in both those receiving pre-protocol
chemotherapy and those without a histologic diagnosis
(Table 3).Follow-up datawere updated in December 2012.Median
follow-upwas 58mo, with aminimum18-mo follow-up for
progression-free patients. There were 48 PFS events and
37 deaths (Fig. 3). The 1-yr PFS rates were 43% (95% CI,
29–57) for BEP and 65% (95% CI, 49–77%) for CBOP/BEP; HR:
0.59 (95% CI, 0.33–1.06). Two-year survival rates were 61%
for BEP and 67% for CBOP/BEP (HR: 0.78 [95% CI, 0.41–1.50]).
There were 14 non-GCT deaths (6 BEP, 8 CBOP/BEP) in
total. In addition to the 10 deaths that occurred during and/
or were considered related to protocol treatment, described
previously, 4 later deaths occurred that were not due to
GCT: two (one in each arm) due to toxicity from second-line
treatment; one thought likely due to recurrent teratoma,
Table 3 – Response to treatment
Response to treatment BEP CBOP/BEP Overall
No. of patients 46 43 89
Favourable: primary analysis, n (%)
Complete response 4 (9) 12 (28) 16 (18)
Partial response: negative markers 23 (50) 18 (42) 41 (46)
Late orchidectomy and partial response* 1 (2) 2 (5) 3 (3)
Nonfavourable, n (%)
No evidence of disease after surgery** 2 (4) 0 (0) 2 (2)
Treatment failure 11 (24) 6 (14) 17 (19)
Mixed response 0 (0) 1 (2) 1 (1)
Death due to germ cell tumour 2 (4) 0 (0) 2 (2)
Death due to toxicity 1 (2) 3 (7) 4 (4)
Death due to other reason 2 (4) 1 (2) 3 (3)
Primary analysis: favourable response, n (%) 28 (60.9) 32 (74.4) 60 (67.4)
90% conﬁdence interval 47.7–73.0 61.2–84.9 58.3–75.6
First sensitivity analysis
Favourable response, n (%) 30 (65.2) 32 (74.4) 62 (69.7)
90% conﬁdence interval 51.1–76.8 61.2–84.9 60.7–77.6%
Second sensitivity analysis
Favourable response, n (%) 27 (58.7) 30 (69.8) 57 (64.0)
90% conﬁdence interval 45.5–71.0 56.3–81.1 54.9–72.5
Subgroupy: patients not given preprotocol chemotherapy
No. of patients 33 32 65
Favourable response, n (%) 22 (66.7) 24 (75.0) 46 (70.8)
90% conﬁdence interval 50.9–80.1 59.4–86.9 60.1–79.9
Subgroupy: patients given pre-protocol chemotherapy
No. of patients 13 11 24
Favourable response, n (%) 6 (46.2) 8 (72.7) 14 (58.3)
90% conﬁdence interval 22.4–71.3 43.6–92.1 39.7–75.4
Subgroupy: patients with a histologic diagnosis at enrolment
No. of patients 29 24 53
Favourable response, n (%) 18 (62.1) 16 (66.7) 34 (64.2)
90% conﬁdence interval 45.1–77.1 47.9–82.2 52.0–75.1
Subgroupy: patients without a histologic diagnosis at enrolment
No. of patients 17 19 36
Favourable response, n (%) 10 (58.8) 16 (84.2) 26 (72.2)
90% conﬁdence interval 36.4–78.8 64.1–95.6 57.4–84.1
BEP = bleomycin, etoposide, and cisplatin; CBOP = carboplatin, bleomycin, vincristine, cisplatin.
* Normal markers, residual nontestis mass remains, postchemotherapy orchidectomy (viable tumour)
** Normal markers, complete resection of residual nontestis mass, viable tumour found.
y The subgroup analysis according to use of pre-protocol chemotherapy was planned; analysis according to histologic diagnosis is exploratory. Of 36 patients
without histology, 10 also had preprotocol chemotherapy.
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ruled out (CBOP/BEP); and one due to primary lung cancer
(BEP).
4. Discussion
The primary efficacy end point was met, with BEP FRRs
approximately as anticipated (61%); the FRRwith CBOP/BEP
was 74%, with the 90% CI excluding rates <60%. This was
supported by encouraging PFS and OS data, particularly
in patients with aggressive disease needing stabilising
chemotherapy; however, acute toxicity with CBOP/BEP was
high. Accrual was slower than anticipated; hence the
criteria for proceeding immediately to phase 3 were not
met, and it is clear that an adequately powered phase 3 trial
would require international collaboration.
The two previous nonrandomised CBOP/BEP studies also
suggested high activity with increased toxicity. The first
[18], in 54 IGCCCG poor-prognosis patients, showed
3-yr relapse-free survival of 83.2% (95% CI, 68.8–91.3)
and 3-yr survival of 91.5% (95% CI, 78.6–96.8). In EuropeanOrganisation for Research and Treatment of Cancer (EORTC)
30948 [19], 29 of 66 eligible patients had poor prognosis.
After a median 40-mo follow-up, 1-yr PFS in the poor-
prognosis group was 81.8% (95% CI, 72.5–91.1). Two-year
survival was 84.5% (95% CI, 75.6–93.3). In both studies, the
major toxicities were haematologic. There were three
treatment-related deaths in the first study but none in
the second.
A systematic review (including searches of Medline,
American Society of Clinical Oncology annual meeting
abstracts [2007–2013], and reference lists from related
reviews [20–22]) identified 12 randomised trials of novel
treatments versus BEP in intermediate- or poor-prognosis
patients (Table4). Even the largestof thesewasonlypowered
to detect an absolute PFS benefit of 15% [3]; several failed to
recruit the targeted sample size. With the exception of the
Genito-Urinary Group of the French Federation of Cancer
Centres (GETUG) 13 trial [23], which randomised a subset of
poor-risk patients showing inadequate marker decline after
1  BEP to continue BEP or switch to a dose-dense regimen,
none show clear superiority over BEP.
[(Fig._3)TD$FIG]
Fig. 3 – Kaplan-Meier plots for (A) progression-free survival and (B) overall survival.
BEP = bleomycin, etoposide, and cisplatin; CBOP/BEP = carboplatin, bleomycin, vincristine, cisplatin/bleomycin, etoposide, and cisplatin.
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notably divergent andweremost favourable in EORTC30974
that closed early due to poor accrual. CBOP/BEP compares
well, demonstrating the greatest estimated relative PFS
benefit over BEP. Both the BEP results and relative benefit are
remarkably similar to those attained in EORTC 30974 [7]
despite what appears to be a higher treatment-related death
rate in the present study. Overall grade 3/4 toxicity rates are
not presented for EORTC 30974, but grade 4 neutropenia
rates were higher arm for arm than in TE23 (47% vs 24% for
BEP; 82% high dose vs 65% CBOP/BEP). Rates of grade 4
leukopenia (11%, 20%) and thrombocytopenia (3%, 12%)across the BEP arms of EORTC trials in intermediate [26] and
poor-prognosis disease [7], respectively, are suggestive of
increased toxicity associated with more advanced disease
even on standard therapy. Nevertheless, these more inten-
sive schedules do carry the risk of increased toxicity, so the
risk–benefit ratio may be debatable. Any such debate does
need to consider the impact of salvage treatment on
cumulative toxicity burden in less intensively treated
patients who relapse.
Restricting more intensive treatment to those most in
need is desirable. Use of dynamic markers to identify
patients who are not responding sufficiently well to
Table 4 – Phase 2 and 3 randomised trials of alternative treatments to standard BEP for intermediate and poor prognosis germ cell tumours
Study Accrual years Prognostic group
(classiﬁcation criteria)
Test
regimen
N (n on test) Event-free survival at 2 yr# (HR < 1.0 favours
test regimen)
Overall survival at 5 yr# (HR < 1.0 favours test
regimen)
BEP Test HR (95% CI) BEP Test HR (95% CI)
De Wit et al. [30] 1983–1987 Poor (EORTC) PVB/BEP 234 (116) 80% 80% – 79% 81% 0.89
Nichols et al. [31] 1984–1989 Poor (Indiana) BEP200 153 (76) 61%* 63%* 0.93 69% 63% 1.25
De Wit et al. [32] 1987–1990 Intermediate
(EORTC)
VIP 87 (46) 85% 85% 0.83 (0.3–2.28) 95%** 98%** 0.39
Nichols et al. [4] 1987–1992 Poor (Indiana) VIP 286 (145) 60% 64% 0.87 66% 68% 0.93
Kaye et al. [3] 1990–1994 Poor (MRC/EORTC)
(63% IGCCCG poor)
BOP/VIP-B 380 (190)
216 (108)
57%
–
49%
–
1.28 (0.95–1.72)
1.04 (0.73–1.50)
73%
–
70%
–
1.30 (0.88–1.92)
0.99 (0.62–1.58)
Culine et al. [24] 1994–2000 All
Intermediate
(IGCCCG)
Poor (IGCCCG)
CISCA/VB 185 (94)
61 (30)
115 (57)
51%
70%
37%
37%
56%
24%
1.32 (0.90–1.92)
1.44
69%
88%
69%
58%
82%
44%
1.37 (0.85–2.17)
2.21
Motzer et al. [6] 1994–2003 All
Intermediate
(IGCCCG)
Poor (IGCCCG)
BEP  2
HD CEC  2
219 (108)
45 (21)
174 (87)
47%
–
45%
50%
–
46%
0.92
0.97
71%
83%
69% at 2 yr
71%
85%
67% at 2 yr
1.0
–
1.08
Di Nicola et al. [25] 1996–2007 Poor (IGCCCG) BEP  2
HD-carboplatin
89 (43) 59% 56% 1.10 67% 61% 1.23
Daugaard et al. [7]
(EORTC 30974)
1999–2007 Poor (IGCCCG) VIP  1
HD VIP  3
131 (65) 45% 58% 0.62 (0.38–1.02) 60% 67% 0.78
De Wit et al. [26]
(EORTC 30983)
1998–2009 Intermediate
(IGCCCG)
T-BEP 337 (168) 75% 82% 0.73 (0.47–1.13) 88% 90% 0.89 (0.46–1.74)
Huddart (NCRI TE23) 2005–2009 Poor (IGCCCG) CBOP/BEP 89 (43) 43% 58% 0.59 (0.33–1.06) 58% at 3 yr 65% at 3 yr 0.78 (0.41–1.50)
Fizazi et al. [23]
(GETUG 13)
Poor (IGCCCG)
with unfavourable
TMD
T-BEP and
Ox  2, PIB  2
203 (105) 48% at 3 yr 59% at 3 yr 0.72 65% at 3 yr 73% at 3 yr 0.73
BEP = bleomycin, etoposide, and cisplatin; BOP/VIP-B = bleomycin, vincristine, cisplatin/etoposide, ifosfamide, cisplatin, and bleomycin; CBOP/BEP = carboplatin, bleomycin, vincristine, cisplatin/bleomycin, etoposide, and
cisplatin; CI = conﬁdence interval; CEC = carboplatin, etoposide, and cyclophosphamide; CISCA-VB = cisplatin, doxorubicin and cyclophosphamide alternated with vinblastine and bleomycin; EORTC = European
Organisation for Research and Treatment of Cancer; GETUG = Genito-Urinary Group of the French Federation of Cancer Centers; HD = high dose; HR = hazard ratio; IGCCCG = International Germ Cell Cancer Collaborative
Group; MRC = Medical Research Council; NCRI = National Cancer Research Institute; NED = no evidence of disease; OX = oxaliplatin; PIB = cisplatin, ifosfamide and bleomycin; PVB = cisplatin, vinblastine, bleomycin; T-
BEP = paclitaxel and bleomycin, etoposide, and cisplatin; TMD = tumor marker decline; VIP = cisplatin, etoposide, and ifosfamide.
# In these columns ‘‘’’ indicates event-free rates estimated from Kaplan-Meier curves and HRs estimated as ln(p2)/ln(p1) where p2 = event-free rate on test, p1 = event-free rate on BEP. * Event-free survival = percentage
continuously NED with median follow-up 2 yr.
** Overall survival = crude survival rate, median follow-up 7.7 yr.
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E U RO P E AN URO LOG Y 6 7 ( 2 0 1 5 ) 5 3 4 – 5 4 3542standard therapy, as in GETUG 13, is a promising strategy,
although the optimal time point to assess rate of marker
decline and the method of intensification is still debatable.
A further potential strategy for which there are limited data
at present [27–29] is dose density, giving BEP every 2 rather
than every 3 wk, with G-CSF support.
5. Conclusions
Improved treatments for poor-prognosis disease that in-
crease cure rate by first-line therapy are needed. At present,
there is no accepted alternative to BEP, and to challenge its
status as standard therapy requires an adequately powered
phase 3 trial. This in turn will need international agreement.
Because CBOP/BEP met its preset activity goals and attained
PFS rates equivalent or better than other approaches to poor-
risk disease, it merits consideration in the development of
any such trial.
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were presented at the ASCO Annual Meeting 2011: Huddart RA, Gabe
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